[go: up one dir, main page]

TR200902782A1 - Canlı aşı bileşimi - Google Patents

Canlı aşı bileşimi

Info

Publication number
TR200902782A1
TR200902782A1 TR2009/02782A TR200902782A TR200902782A1 TR 200902782 A1 TR200902782 A1 TR 200902782A1 TR 2009/02782 A TR2009/02782 A TR 2009/02782A TR 200902782 A TR200902782 A TR 200902782A TR 200902782 A1 TR200902782 A1 TR 200902782A1
Authority
TR
Turkey
Prior art keywords
vaccine composition
live vaccine
virulent
promoter
copolymer
Prior art date
Application number
TR2009/02782A
Other languages
English (en)
Inventor
Kalthoff Donata
Beer Martin
Küster Heike
Original Assignee
Riemser Arzneimittel Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riemser Arzneimittel Ag filed Critical Riemser Arzneimittel Ag
Publication of TR200902782A1 publication Critical patent/TR200902782A1/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation
    • C12N2710/16762—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Bir canlı aşı maddesi bileşimi uygun bir taşıyıcının içinde bir gE ve TK silme - çıkartma işlemi uygulanmış BHV-1 mutasyonunu ve bir virüs öldürücü olmayan destekçiyi içerir. Virüs öldürücü olmayan destekçi bir Polymer, özellikle de bir Copolymer veya Block Copolymer veya Polygen TM'dir. Virüs öldürücü olmayan destekçinin oranı % 5 ila % 50 (v/v), tercihen de % 10 ila % 15 (v/v) kadardır Canlı aşı maddesi bileşimi BHV-1 enfeksiyonlarından ve BHV-1 den türeyen hastalıklardan koruyucu olarak bir tıbbı ilaç formülünün üretilmesi için kullanılır.
TR2009/02782A 2008-04-10 2009-04-09 Canlı aşı bileşimi TR200902782A1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08007133A EP2108375A1 (de) 2008-04-10 2008-04-10 Lebendimpfstoffzusammensetzung

Publications (1)

Publication Number Publication Date
TR200902782A1 true TR200902782A1 (tr) 2009-10-21

Family

ID=39790174

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2009/02782A TR200902782A1 (tr) 2008-04-10 2009-04-09 Canlı aşı bileşimi

Country Status (5)

Country Link
EP (1) EP2108375A1 (tr)
CZ (1) CZ20656U1 (tr)
DE (1) DE202009002058U1 (tr)
SE (1) SE0950224L (tr)
TR (1) TR200902782A1 (tr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102649948B (zh) * 2011-02-23 2016-05-25 华中农业大学 牛传染性鼻气管炎ΔTK/ΔgE基因缺失标志活疫苗及制备方法
CN105368791A (zh) * 2014-02-21 2016-03-02 普莱柯生物工程股份有限公司 一种猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9100989A (nl) * 1991-06-07 1993-01-04 Stichting Centr Diergeneeskund Bovine herpesvirus type 1 deletiemutanten, daarop gebaseerde vaccins, diagnostische kits voor detectie van bovine herpesvirus type 1.

Also Published As

Publication number Publication date
DE202009002058U1 (de) 2010-02-25
CZ20656U1 (cs) 2010-03-22
SE0950224L (sv) 2009-10-11
EP2108375A1 (de) 2009-10-14

Similar Documents

Publication Publication Date Title
EA201390630A1 (ru) Композиции микобактериальных антигенов
ATE484539T1 (de) Polysiloxan-/polyimid-copolymermischungen
EA201491337A1 (ru) Композиции и способы для обработки смолы в скважине
TR201909466T4 (tr) Düşük serbest stearik asit içeren veya tespit edilebilen hiç serbest stearik asit içermeyen, stearik asitle işlenmiş kalsiyum karbonat bileşimleri ve ilgili yöntemler.
RU2008147883A (ru) Применение молочнокислых бактерий для уменьшения детской колики
RS52845B (en) TREATMENT PROCEDURES USING GLYCOPEGILATED G-CSF
MX2009012694A (es) Composicones y metodos utiles para modular la inmunidad, mejorar la eficacia de vacunas, disminuir la morbilidad asociada con infecciones cronicas por fhv-1, y prevenir o tratar la conjuntivitis.
NZ590864A (en) Compositions comprising very low density polyethylene, ethylene acrylic acid copolymer and thermoplastic starch
IL186986A0 (en) Compositions and methods for modulating immune responses
BR112012021337A2 (pt) formulações de apixaban.
PH12013502192A1 (en) Antibodies against human angiopoietin 2
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
FR2903574B1 (fr) Granules de cysteine et leurs utilisations a titre d'activateurs de croissance de bifidobacterium animalis lactis.
TR201906664T4 (tr) Doymuş polimer içerikli izosorbid içeren reçine kompozisyonu.
TR200902782A1 (tr) Canlı aşı bileşimi
BR112012031311A2 (pt) "material polimérico conjugado e seus usos"
MA33022B1 (fr) Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil
ATE547479T1 (de) Polycarbonatzusammensetzungen, herstellungsverfahren dafür und artikel damit
DE602005011330D1 (de) Sulfonatfunktionelle organopolysiloxane
DE602007010488D1 (de) Kosmetische zusammensetzungen mit ethylenbrassylat
EA201001599A1 (ru) Косметические и дерматологические композиции, содержащие интерлейкин-1 альфа
RS53197B (en) OSTEOARTRITIS TREATMENT COMBINATION
HRPK20070344B3 (en) Yoghurt with propolis and pollen
AR068777A1 (es) Composicion de champu acondicionadora
WO2010078183A3 (en) Method of generating regulatory t cells using cord blood and adult blood cd14+ monocyte cells